In addition, the percentage of patients with detectable PV‐1 increased in a stage‐dependent manner: 68% in AD (53/78), 71% in ACLF grade 1 (15/21), 100% in ACLF grade 2/3 (21/21); p < 0.001. This evidence concerns the gene PLVAP and Alzheimer disease.